Fujifilm Kyowa Kirin JV lines up bevacizumab as next biosimilar target
This article was originally published in Scrip
Executive Summary
Fujifilm Kyowa Kirin Biologics, the equally owned joint venture between Japan's Fujifilm and Kyowa Hakko Kirin, has unveiled Roche/Genentech's big-selling anticancer antibody Avastin (bevacizumab) as the next project in its growing pipeline of biosimilars.